Search

Displaying results 1861 - 1870 of 5419 in total
  1. Drug

    Paliperidone

    go.drugbank.com/drugs/DB01267
    ApprovedInvestigational

    The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. … Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006.

  2. Drug

    Apalutamide

    go.drugbank.com/drugs/DB11901
    ApprovedInvestigational

    Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death [A31846]. … Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant

  3. Drug

    Cantharidin

    go.drugbank.com/drugs/DB12328
    ApprovedInvestigational

    [A32892] Nevertheless, it gained its first FDA approval on Jul 21, 2023, under the brand name YCANTH™ by Verrica Pharmaceuticals for the treatment of molluscum contagiosum in adult and pediatric patients

  4. Drug

    Tyrosine

    go.drugbank.com/drugs/DB00135
    ApprovedInvestigationalNutraceutical

    Tyrosine is a non-essential amino acid. In animals it is synthesized from phenylalanine. It is also the precursor of epinephrine, thyroid hormones, and melanin.

  5. Drug

    Sipavibart

    go.drugbank.com/drugs/DB21908
    ApprovedInvestigational

    [A274098] It works by binding to the SARS-CoV-2 spike protein receptor binding domain (RBD), neutralize the virus and preventing its entry into the host cell.

    Categories: Antiinfectives for Systemic Use
  6. Drug

    Cladribine

    go.drugbank.com/drugs/DB00242
    ApprovedInvestigational

    Cladribine is a purine analogue or a chlorinated derivative of adenine that causes apoptosis of B and T lymphocytes. Cladribine was first approved in the United States in 1993 initially as a treatment for a number of hematological malign...

  7. Drug

    Paritaprevir

    go.drugbank.com/drugs/DB09297
    ApprovedInvestigational

    By inhibiting viral protease NS3/4A, paritaprevir therefore prevents viral replication and function. … More specifically, paritaprevir prevents viral replication by inhibiting the NS3/4A serine protease of Hepatitis C Virus (HCV) [FDA Label].

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  8. Drug

    Terfenadine

    go.drugbank.com/drugs/DB00342
    ApprovedWithdrawn

    In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.

    Categories: Antihistamines for Systemic Use
  9. Drug

    Nilutamide

    go.drugbank.com/drugs/DB00665
    ApprovedInvestigational

    Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors).

  10. Drug

    Batroxobin

    go.drugbank.com/drugs/DB09005
    Investigational

    Currently use is experimental but trials have been conducted which support certain clinical applications. Recombinant Batroxobin in relatively affordable and could be accessed by mass production. … Batroxobin is inactivated by alpha2-macroglobulin, but not anti-thrombin compounds. Batroxobin will also bind fibrinogen in a manner different than thrombin and with a higher affinity.